Novartis to shutter NC-based Sandoz plant ahead of spinoff
As Sandoz is ready to spin out from Novartis, the parent company is shuttering an oral solid dosage plant in Wilson, North Carolina.
The plant, which makes tablets and capsules for Canada and the US, employs about 246 people who have already been alerted to the closure, a Novartis spokesperson told several media outlets. But most of the employees are likely to be let go, unless there is a “late sale of the site” to a buyer interested in retaining staff, a spokesperson said.
Novartis also said the decision to close the site came prior to the spin-off decision, and prior to the large biopharma company’s decision to cut about 8,000 jobs globally as it integrates its pharmaceuticals and oncology business units.
“To begin and to be clear, the process to review the Wilson site and the decision to close the site had been initiated long before the announcement of the Strategic Review, and regardless of any strategic review outcome. It is the nature of the generics business to constantly look for opportunities to become more efficient,” the Novartis spokesperson added to the other outlets.
Novartis has another North Carolina-based manufacturing facility, located in the heart of the Research Triangle Park in Durham, which won clearance in April as the second site to produce Zolgensma — the first one was in Libertyville, IL, approved in 2019.